WallStreetZenWallStreetZen

NASDAQ: HHS
Harte Hanks Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their HHS stock forecasts and price targets.

Forecast return on equity

Is HHS forecast to generate an efficient return?
Company
50.24%
Industry
55.49%
Market
32.8%
HHS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HHS forecast to generate an efficient return on assets?
Company
8.84%
Industry
9.88%
HHS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HHS earnings per share forecast

What is HHS's earnings per share in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$0.58
Avg 2 year Forecast
$1.39

HHS revenue forecast

What is HHS's revenue in the next 2 years based on estimates from 2 analysts?
Avg 1 year Forecast
$194.3M+2.35%
Avg 2 year Forecast
$202.1M+6.48%
HHS's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

HHS revenue growth forecast

How is HHS forecast to perform vs Conglomerates companies and vs the US market?
Company
2.35%
Industry
-3.81%
Market
14.96%
HHS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
HHS's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

HHS vs Conglomerate Stocks

TickerPricePrice TargetUp/downsideConsensus
HHS$8.38N/AN/A
ALPP$0.50N/AN/A
EFSH$2.71N/AN/A
RCMT$19.76$33.00+67.05%Strong Buy
TUSK$3.54N/AN/A

Harte Hanks Stock Forecast FAQ

What is HHS's earnings growth forecast for 2024-2025?

(NASDAQ: HHS) Harte Hanks's forecast annual earnings growth rate of N/A is not forecast to beat the US Conglomerates industry's average forecast earnings growth rate of 19.95%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.28%.

Harte Hanks's earnings in 2024 is -$950,000.On average, 2 Wall Street analysts forecast HHS's earnings for 2024 to be $4,163,520, with the lowest HHS earnings forecast at $4,054,907, and the highest HHS earnings forecast at $4,272,134.

In 2025, HHS is forecast to generate $10,028,653 in earnings, with the lowest earnings forecast at $9,413,177 and the highest earnings forecast at $10,644,130.

If you're new to stock investing, here's how to buy Harte Hanks stock.

What is HHS's revenue growth forecast for 2024-2025?

(NASDAQ: HHS) Harte Hanks's forecast annual revenue growth rate of 2.35% is forecast to beat the US Conglomerates industry's average forecast revenue growth rate of -3.81%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.96%.

Harte Hanks's revenue in 2024 is $189,820,000.On average, 2 Wall Street analysts forecast HHS's revenue for 2024 to be $1,406,719,578, with the lowest HHS revenue forecast at $1,405,459,661, and the highest HHS revenue forecast at $1,407,979,495.

In 2025, HHS is forecast to generate $1,463,567,923 in revenue, with the lowest revenue forecast at $1,463,386,901 and the highest revenue forecast at $1,463,748,946.

What is HHS's forecast return on assets (ROA) for 2024-2025?

(NASDAQ: HHS) forecast ROA is 8.84%, which is lower than the forecast US Conglomerates industry average of 9.88%.

What is HHS's Earnings Per Share (EPS) forecast for 2024-2025?

(NASDAQ: HHS) Harte Hanks's current Earnings Per Share (EPS) is -$0.12. On average, analysts forecast that HHS's EPS will be $0.58 for 2024, with the lowest EPS forecast at $0.56, and the highest EPS forecast at $0.59. In 2025, HHS's EPS is forecast to hit $1.39 (min: $1.30, max: $1.47).

What is HHS's forecast return on equity (ROE) for 2024-2025?

(NASDAQ: HHS) forecast ROE is 50.24%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.